FOLD
Amicus Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +15.4% ·
share flow +11.0% ·
net new positions +13.3%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 106 | -6 | 206.15M | $2.98B | +6 | −13 |
| Q4 2025 | 112 | +4 | 192.14M | $2.74B | +5 | — |
| Q3 2025 | 19 | -1 | 150.66M | $1.19B | — | −2 |
| Q2 2025 | 18 | 0 | 135.88M | $778.62M | — | — |
| Q1 2025 | 15 | +2 | 70.64M | $576.46M | +2 | — |
| Q4 2024 | 13 | -1 | 63.65M | $599.56M | — | −1 |
| Q3 2024 | 13 | +2 | 42.84M | $457.59M | +2 | — |
| Q2 2024 | 11 | — | 38.85M | $385.40M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 29.20M | +2.6% | $238.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 9.52M | -8.1% | $77.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 7.84M | -4.9% | $63.97M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 7.84M | -4.9% | $63.97M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 6.76M | +2.3% | $55.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 6.76M | +2.3% | $55.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Millennium Management ✦ | 3.36M | +635.1% | $27.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 3.24M | +5.0% | $26.40M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 2.99M | New | $24.36M | 0.1% | New | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 2.29M | +46.8% | $18.69M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 2.29M | +46.8% | $18.69M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 1.56M | -25.9% | $12.75M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 1.39M | +368.2% | $11.36M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 1.28M | -6.2% | $10.47M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 1.28M | -6.2% | $10.47M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | PRIMECAP Management ✦ | 919.50K | -1.6% | $7.50M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Marshall Wace ✦ | 196.11K | +168.8% | $1.60M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 53.99K | New | $440,558 | 0.0% | New | 1 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 42.45K | -53.0% | $346,425 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 42.45K | -53.0% | $346,425 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 42.45K | -53.0% | $346,425 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 42.45K | -53.0% | $346,425 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $24.36M | 0.1% |
| Gotham Asset Management | $440,558 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 296 holders, 325.04M shares, $4.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.